254 related articles for article (PubMed ID: 8951781)
1. Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".
Najean Y; Rain JD; Dresch C; Goguel A; Lejeune F; Echard M; Grange MJ
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():111-9. PubMed ID: 8951781
[TBL] [Abstract][Full Text] [Related]
2. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group.
Najean Y; Rain JD
Blood; 1997 Apr; 89(7):2319-27. PubMed ID: 9116275
[TBL] [Abstract][Full Text] [Related]
3. Treatment of polycythaemia vera and essential thrombocythaemia.
Tefferi A; Silverstein MN
Baillieres Clin Haematol; 1998 Dec; 11(4):769-85. PubMed ID: 10640216
[TBL] [Abstract][Full Text] [Related]
4. Indications, procedure and results for the treatment of polycythaemia vera by bleeding, pipobroman and hydroxyurea.
Boivin P
Nouv Rev Fr Hematol (1978); 1993; 35(5):491-8. PubMed ID: 8295823
[TBL] [Abstract][Full Text] [Related]
5. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
6. [Efficacious treatment of a fatal blood disease: polycythemia vera].
Sánchez Fayos J; Román Barbero A; Nevado Reviriego I
Sangre (Barc); 1997 Jun; 42(3):215-8. PubMed ID: 9381264
[No Abstract] [Full Text] [Related]
7. [Treatment of polycythemia. II.--Comparison of hydroxyurea with pipobroman in 294 patients less than 65 years of age].
Najean Y; Rain JD; Lejeune F; Echard M; Fermand JP; Gruyer P; Brahimi S
Ann Med Interne (Paris); 1998 Mar; 149(2):94-100. PubMed ID: 11490531
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of polycythemia with 32P with or without hydroxyurea maintenance therapy. Preliminary results in 237 elderly and high vascular risk subjects studied since 1980].
Najean Y; Rain JD; Toubert ME
Presse Med; 1993 Dec; 22(39):1951-6. PubMed ID: 8121914
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of polycythemia vera with hydroxyurea or pipobroman. Efficacy and toxicity analysed from a protocol of 96 patients under 65 years of age. Le Groupe d'Etude des Polyglobulies].
Najean Y
Presse Med; 1992 Nov; 21(37):1753-7. PubMed ID: 1488420
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of polycythemia. I--Using radiophosphorus with or without treatment in 483 patients over 65 years of age].
Najean Y; Rain JD; Goguel A; Grange MJ; Vigneron N; Dupuy E; Mougeot-Martin M
Ann Med Interne (Paris); 1998 Mar; 149(2):87-93. PubMed ID: 11490530
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy.
Kiladjian JJ; Gardin C; Renoux M; Bruno F; Bernard JF
Hematol J; 2003; 4(3):198-207. PubMed ID: 12764352
[TBL] [Abstract][Full Text] [Related]
12. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years.
Najean Y; Rain JD
Blood; 1997 Nov; 90(9):3370-7. PubMed ID: 9345019
[TBL] [Abstract][Full Text] [Related]
13. Clinical and laboratory assessment and therapeutic problems in longstanding polycythaemia vera.
Rain JD
Nouv Rev Fr Hematol (1978); 1994 Apr; 36(2):197-203. PubMed ID: 8036142
[TBL] [Abstract][Full Text] [Related]
14. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
[TBL] [Abstract][Full Text] [Related]
15. [Hydroxyurea--is it a harmless drug in Vaquez disease?]].
Rain JD
Pathol Biol (Paris); 2001 Mar; 49(2):158-63. PubMed ID: 11317962
[TBL] [Abstract][Full Text] [Related]
16. The very-long-term course of polycythaemia: a complement to the previously published data of the Polycythaemia Vera Study Group.
Najean Y; Dresch C; Rain JD
Br J Haematol; 1994 Jan; 86(1):233-5. PubMed ID: 8011542
[TBL] [Abstract][Full Text] [Related]
17. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980.
Kiladjian JJ; Chevret S; Dosquet C; Chomienne C; Rain JD
J Clin Oncol; 2011 Oct; 29(29):3907-13. PubMed ID: 21911721
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
Berk PD; Goldberg JD; Donovan PB; Fruchtman SM; Berlin NI; Wasserman LR
Semin Hematol; 1986 Apr; 23(2):132-43. PubMed ID: 3704665
[TBL] [Abstract][Full Text] [Related]
19. Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies.
Ellis JT; Peterson P; Geller SA; Rappaport H
Semin Hematol; 1986 Apr; 23(2):144-55. PubMed ID: 3704666
[TBL] [Abstract][Full Text] [Related]
20. Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman.
Passamonti F; Lazzarino M
Leuk Lymphoma; 2003 Sep; 44(9):1483-8. PubMed ID: 14565648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
